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Abstract We determined whether the cell permeable molecule 
AICAR, whose metabolite activates AMP-activated protein 
kinase (AMPK) in cells, affected glycogen metabolism in rat 
soleus muscle preparations in vitro. The basal and insulin- 
stimulated rates of radioehemical lactate formation, net lactate 
release and glycogen synthesis were determined. AICAR 
stimulated net lactate release (but not radluchemical lactate 
formation) only at a basal concentration of insulin. An incteascd 
rate of glyeegenolysis was the likely cause of increased net 
lactate release as glycogen phosphorylase activity was signifl- 
candy increased by AICAR. AICAR-stimulated net lactate 
release and phosphorylase activity were potently inhibited by 
insulin. 
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1. Introduction 
Insulin is a potent stimulator of g.~tcose transport and in- 
tracellular glucose disposal in skeletal muscle. Insulin regu- 
lates glucose disposal by controlling the recruitment of 
GLUT 4 glucose transporter protein to the cellular membrane 
and the activity of key enzymes uch as hexokinase-lI, glyco- 
gen synthase and phosphorylase. Recently, it has been sug- 
gested that in skeletal muscle glycogenolysis i  more sensitive 
to insulin than is glucose transport and/or phosphorylation 
[1]. Glycogen phosphorylase, the flux-generating enzyme of 
glycogenolysis, is an important determinant of the rate of 
glycogenolysis. Acute regulation of glycogen phosphorylase 
activity consists of allosteric modulators and protein phos- 
phorylation. However, the regulation of phosphorylase activ- 
ity in skeletal muscle is not completely understood [2]. 
Several enzymes are potential substrates for AMP-activated 
protein kinase (AMPK), including glycogen synthase and 
phosphorylase kinase [3]. AMP-kinase is acknowledged as 
performing a major role in regulating lipid metabolism in 
adipose cells [4--6] and liver cells [7-9]. AICAR is a cell perme- 
able molecule that is taken up readily by ceils (probably by 
the adenosine transporter) and phosphorylated, byadenosine 
kinase [10], to ZMP. Thereafter ZMP may be metabolised to 
inosine monophosphate (IMP) or ZDP or ZTP [10]. AICAR 
is conve~'ted to ZMP which affects a number of metabolic 
processes in adipocytes [6] and hepatocytes [11]. Recently, 
evidence for the metabolic effects of AICAR being mediated 
via activation of AMPK has been reported from experiments 
with adipocytes [6,12] and hepatocytes [12]. An elevation of 
ZMP will mimic the effect of AMP which activates AMPK 
both by direct allosteric activation [13] and via promoting 
increased phosphorylation catalysed by a kinase kinase [14]. 
AICAR is taken up by skeletal muscle cells and metabolised 
to ZMP [15,16] but the effects of AICAR on glucose metabo- 
lism in muscle have not been reported. 
As glycogen synthase and phosphorylase kinase are poten- 
tial substrates for AMPK [7] we hypothesised that incubation 
of skeletal muscle preparations with AICAR would lead to 
alterations in the catalytic activities of these enzymes (via 
ZMP and possible ZMP activated AMPK) which would result 
in the inhibition of glycogen synthesis and activation of gly- 
cogen breakdown. We also investigated whether insulin had 
any effect on glycogen metabolism altered by AICAR. 
2. Materials and methods 
2.1. Animals 
Male Wistar ats (130-140 g) were purchased from Harlan-Olac, 
Bicester, UK, and were kept in the Departmental animal house until 
experimentation. The animals were housed in groups of six under a 
controlled 12-h light--dark cycle (lights on from 08.00 to 20.00 h). 
Food (standard laboratory chow supplied by SDS, Whitmam, UK; 
digestible carbohydrate 52%, protein 16%, fat 2%, non-digestible re-
sidue 30% all by weight) and water were provided ad libitum, until 
12 h before the animals were killed. Stripped soleus muscle was rou- 
tinely prepared between 08.30 to 09.30 h. 
2.2. Incubation procedures 
Rats were killed by cervical dislocation, and soleus muscles were 
isolated and dissected longitudinally, rapidly weighed and tied at the 
resting length in situ on stainless steel clips, and placed in 25-ml 
Erlenmeyer flasks containing oxygenated (3 ml) Krebs-Ringer bicar- 
bonate buffer (pH 7.4), with 5.5 mM glucose and 10 ItUIml insulin, as 
previously described [17,18]. Muscles were pre.incubated with shaking 
(100 rpm) for 40 min in sealed flasks at 370C and then transferred to 
separate flasks containing Krebs-Ringer bicarbonate buffer (3 ml) 
containing 5.5 mM glucose (0.5 I~Ci [U-~4C]glucose/ml), 1% bovine 
serum albumin, and insulin at the concentration given in the section 
3.1-3.8 (the details of the protocol have been given previously [17.18]. 
When phosphorylase activity was measured in the isolated incubated 
soleus muscle preparations [U-14C]glucose was omitted from the med- 
ium. In addition, where the effects of AICAR were tested, ! mM 
AICAR was added to both the pre-incubation a d the incubation 
flasks (i.e. muscle incubated for 100 min with AICAR). 
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2.3. Measurement of glycolysis and glycogen synthesis 
After 60 min of incubation at 370C, muscles were removed from the 
incubation flasks and frozen in liquid nitrogen; the concentration f 
lactate in the medium was always determined. In certain cases the rate 
of incorporation f[U-~4C]glucose into glycogen, the rate of release of 
[~4C]lactate into the medium, and the activity of glycogen phosphor- 
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ylase were determined, l'lC-radiolabelled lactate release is a good in- 
dicator of the rate of glucose transport into isolated incubated skeletal 
muscle preparations [19]. Net lactate release is a term used to describe 
lactate that can arise from glucose transported into the cell and glu- 
cosyl units release from glycogen breakdown. 
2.4. Glycogen phosphorylase assay 
Frozen muscle tissue was crushed and homogenized (10 s) in 1 ml 
of 20 mM 6.phosphoglycerate nd 200 pl of Solution A [60% (vol/voi) 
glycerol, 20 mM NaF and 1 mM EGTA; pH 7.5] by use ofa polytron 
homogeniser [20]. The homogenate was centrifuged for 2 rain at 
13000×g. The supernatant was diluted 1:1 with buffer B (50 mM 
MES, 50 mM KF and 60 mM j]-mercaptoethanol; pH 6.1). The 
diluted supernatant (0.06 ml) was mixed with 100 p.I of the reaction 
mixture C (400 mM KF, 2 mg/mi glycogen, 27.88 mg/ml glucose-l- 
phosphate, 0.5 IxCi/ml [U-14C]glucose l-phosphate, and various test 
metabolites -- see section 3.2) and incubated for I h at 30°C. A 
portion of the mixture (0.08 ml) was removed and placed onto 
20× 20 mm 3M chromatography paper, The paper was dropped im- 
mediately into 66% (vlv)-ethanoi (4°C). Three separate washes in ice- 
cold 66% (v/v) ethanol were preformed, The papers were removed and 
bathed in acetone for 2-3 min before being dried, Each paper was 
covered with scintillation fluid before being counted in a scintillation 
counter, A wash blank was preformed with Buffer A (0.06 ml), Re- 
sults are expressed as pmolcs of glucosyl units assimilated into glyco- 
gen per minute per gram of protein in the diluted supernatant (pmoll 
rain per g protein). Protein content was measured by the Bio-Rad 
assay, 
2,5, Statistical nalysis 
Student's I test was used for comparison of significance of differ- 
ences between two sample means. 
3, Results 
3.1. Glycogen synthesis and glycolysis 
AICAR did not alter the rate of glycogen synthesis in rat 
soleus muscle preparations at either a basal or a maximally- 
stimulating concentration of insulin (i.e, 10 and 1000 pUnits/ 
ml; see Fig. I), The effects of AICAR on basal and insulin- 
stimulated ratt;s of net lactate release are given on Fig, 2, 
AICAR had no effect on glycolysis in the presence of a sub- 
maximal (100 lzUnit~ml) or maximal concentration of insulin, 
4 
| ,  
1, 
O' 
10 1000 
Insulin Canuntrstlcm (punlta/ml) 
Fig, I, Eff~t of I mM AICAR on basal and insulin-stimulated 
rates of glycogen synthesis in incubated soleus muscle preparations. 
AICAR was added to the pr~incubation and incubation media. 
The results are presented as the mean values _+ S,E,M, for at least 
ten separate incubations, 
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Fig. 2. Effect of I mM AICAR on basal and insulin-stimulated net 
lactate release in isolated incubated soleus muscle preparations. AI- 
CAR was added to the pre-incubation and incubation media. Tile 
results are presented as the mean values + S.E.M. for at least ten 
separate incubations. Significant differences from control values are 
indicated by ***P < 0.001. 
However, at a basal concentration of insulin there was a sig- 
nificant increase in the rate of lactate release (Fig. 2). The 
increased rate of lactate release may be the result of increased 
rate of glucose transport which would be indicated by an 
increase in the rate of ]4C-labelled lactate release. AICAR 
(I raM) [4.26 + 0.45 pmol/h per g wet wt. (10)] did not affect 
the basal rate of l'lC-labelled lactate release compared with 
control a value [3.98 + 0.37 pmollh per g wet wt. (10)]. 
3,2. Phosphorylase activity 
The activity of glycogen phosphorylase was assayed in rat 
soleus muscle preparations incubated with a basal concentra- 
tion of insulin (10 I~Units/ml) and in the, absence or presence 
of AICAR (! raM). AICAR significantly il,~creased (55%)gly- 
cogen phosphorylase activity in isolated incubated soleus mus- 
cle preparations (Fig. 3a). 
Effectors (AMP or AICAR or ZMP) that might have al- 
tered phosphorylase activity in vitro were added to the muscle 
hamogenates prepared from soleus muscle preparations incu- 
bated with or without AICAR (Fig. 3b). AMP (4 raM), as 
previously reported [2], significantly increased the activity of 
glycogen phosphorylase in muscles incubated in the absence 
or presence of AICAR (Fig. 3b). Furthermore, AICAR pres- 
ent in the incubation medium caused a significantly additive 
increase in phosphorylase activity already stimulated with 
AMP (Fig. 3b). AICAR (4 raM) added to the glycogen phos- 
phorylase reaction mixture did not affect phosphorylase activ- 
ity in muscle preparations incubated in the absence or pres- 
ence of AICAR (Fig. 3b). However, the phosphorylated form 
of AICAR, ZMP (4 raM), did significantly increase the phos- 
phorylase activity by a similar magnitude as that seen with 
4 mM AMP (Fig. 3b). The concentration-dependent effects of 
AMP and ZMP on the phosphorylase activity were measured 
in fresh (i.e. non-incubated) soleus muscle homogenates (Fig. 
4). The percentage stimulation of phosphorylase activity was 
49%, 100%o, 146%, 177% and 162% at 0.075, 0.2, 0.5, 4 and 10 
mM AMP, respectively (see Fig. 4). ZMP significantly stimu- 
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Fig. 3. Glycogen phosphorylase activity in homogenates prepared 
from solei incubated in the absence or presence of AICAR (a) and 
in homogenates incubated with AMP, AICAR or ZMP (all at 
4 mM) (b). Glycogen phosphorylaso activity was assayed as de- 
scribed in section 2.4. Muscles were incubated with or without AI- 
CAR before measurement of phosphorylase activity (Fig. 4a). AMP, 
AICAR or ZMP (all 4 raM) were added to muscle homogenates 
prepared from solei incubated with or without AICAR (b). The re- 
sults are presented as the mean values + S.E.M. for at least ten se- 
parate incubations. Significant difference from control values are in- 
dicated by **P < 0.01 or *P < 0.05. 
lated phosphorylase activity at 0.2 mM 07%), 0.5 mM (71%) 
and 4 mM (174%). 
3.3. Effect of insulin 
The effect of insulin on AlCAR-stimulated rates of lactate 
release and glycogen phosphorylase activity are given in Fig. 
5. AICAR significantly stimulated both lactate release and 
phosphorylase activity (Fig. 5). Insulin, at a sub-maximal con- 
centration of 100 [.tUnitslml, deceased the AICAR-stimulated 
rate of lactate release by 89% and phosphorylase activity by 
78% (Fig. 5). 
4. Discussion 
The aim of the present study was to determine the meta- 
bolic effects of AICAR on glycogen metabolism in an isolated 
incubated rat skeletal muscle preparation. AICAR had no 
effect on basal or insulin-stimulated glycogen synthesis (Fig. 
1). However, the presence of AICAR (I mM) in the pre-in- 
cubation and incubation medium caused a significant increase 
in the rate of net lactate release in soleus muscle preparations 
at a basal, but not at sub-maximal or maximal concentrations 
of insulin (Fig. 2). The basal rate of 14C-labelled lactate re- 
lease was not affected by AICAR (see section 3.1) which in- 
dicated that the rate of glucose transport into the muscle cells 
was unaffected. This suggested that AICAR stimulated the 
rate of glycogenolysis, which was confirmed by the fact that 
AICAR significantly increased glycogen phosphorylase activ- 
ity in isolated incubated rat soleus muscle preparations (Fig. 
3a and b). AICAR did not activate glycogen phosphorylase 
activity in skeletal muscle homogenates (Fig. 3b) which dem- 
onstrates the need for AICAR to be converted to an active 
metabolite (i.e. ZMP). 
Glycogen phosphorylase exists in two forms, a and b, which 
are interconvertible via phosphorylation (by phosphorylase 
kinase) and dephosphorylation (by a phosphatase). In resting 
muscle, most (probably 99%) of the phosphorylase is in the 
b-form [21]. Phosphorylase b can be activated by phosphate, 
AMP and IMP. In resting muscle the concentration of phos- 
phate, AMP and IMP are such that the phosphorylase b form 
is not activated. Very large changes in the concentration of 
phosphate, AMP and IMP are required to activate phosphor- 
ylase b. 
We can postulate r,bout the mechanism(s) for AICAR-stim- 
ulated glycogenolyis in skeletal muscle. Two hypotheses can 
be forwarded. Firstly, the accumulation of ZMP and/or IMP 
in soleus muscle preparations in vitro leads to an allosteric 
activation of glycogen phosphorylase. Secondly, accumulation 
of ZMP binds to AMPK and this results in activation of this 
enzyme. AMPK can phosphorylate phosphorylase kinase in 
vitro [3], although whether this occurs in vice to change cat- 
alytic activity has yet to be demonstrated. The activated phos- 
phorylase kinase would provide a mechanism for activation of 
both glycogen phosphorylase and glycogenolysis. 
The concentrations of ZMP and IMP necessary for half- 
maximal activation of phosphorylase b are about 0,6 mM (see 
Fig. 4) and 1-2 raM, respectively. These concentrations are 
equivalent o a muscle content of between 0.7 to 1.4 ~mollg 
wet wt. During infusion of 8 millimoles of AICAR to dogs 
over 40 rain the peak concentration of AICAR in the plasma 
at the end of infusion is 0.336 mM [22,23]. ZMP content 
reached a maximum of 0.032 ~mol/g wet wt. and IMP content 
is 0.05 ~mol/g wet wt. Assuming a cytosol water content of 
0.52 ml/g [24] and a linear concentration and time-dependent 
relationship for AICAR phosphorylation to ZMP and IMP 
(for both in vice and in vitro) the highest estimated concen- 
trations for these metabolites in soleus muscle cells are about 
460 and 720 ~tM, respectivel). Hepatocytes incubated with 0.5 
mM AICAR have an intracellular concentration of ZMP of 
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Fig. 4. Effects of AMP or ZMP on glycogen phosphorylase activity 
in muscle homogenates prepared from rat solei. Solei were rapidly 
isolated and immediately frozen in liquid nitrogen. Results are pre- 
sented as the percentage increase in phosphorylase activity in the 
presence of metabolite compared with the activity in the absence of 
metabolite. N.D. means not determined. The results are given as 
mean values + S.E.M. for at least 5 separate observations. 
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Fig. 5, Effects of insulin on the percentage increase of AICAR-sti- 
mulated glycogen phosphoryla~e activity and net lactate release in 
soleus muscle in vitro. Glycogen phosphorylase activity was assayed 
as described in section 2.4. Muscles were incubated with AICAR 
and ! or 10 I~Units of insulin/ml before measurement of phosphory- 
lass activity and net lactate release. The results are given as mean 
values :1: S.E.M. for at least 8 separate observations. Significant dif- 
ferences from control values are indicated by ***P < 0.001. 
10 mM. This concentration could not occur in rat skeletal 
muscle because the activity of adenosine kinase, the key reg- 
ulatory enzyme for adenosine (AICAR) phosphorylation, is 
50-fold higher in rat liver [25]. Therefore, it would seem un- 
likely that opon AICAR metabolism the concentrations of
ZMP and/or IMP are sulficiently high enough for them to 
act as direct allosteric activators of glycogen phosphorylase 
in muscle. Also, the glycogen phosphorylase assay involves a 
130-fold dilution of the homogenate and, therefore, the aUo- 
steri¢ effect of ZMP on phosphorylase would be lost. It is 
clear that in soleus muscle preparations incubated with AI- 
CAR a significant effect on phosphorylase does survive the 
homogenisation procedure, even with AMP (Fig, 31)), This 
must mean AICAR stimulated phosphorylase activity is by 
a different mechanism. 
We suggest hat ZMP (from AICAR) activates AMPK 
which phosphorylates, to activate, phosphorylase kinase 
which is the kinase responsible for activation of glycogen 
phosphorylase, AMPK activity, although low, is detectable 
in skeletal muscle [26]. The half.maximal effect of AMP on 
rat liver AMPK is between 4,4 and 29 pM (depending on the 
assay buffer ATP concentration) [20]. ZMP is known to mimic 
the effects of AMP by allostericaily activating rat and human 
liver AMPK and rat adipocyte AMPK [8]. ZMP is both an 
allosteric activator of AMPK and, via AMP-activated protein 
kinase kinase, promotes the re-activation of dephosphorylated 
AMPK [14], The K~ for allosteric activation of AMPK by 
ZMP is 81 pM (rat liver) or 103 pM (rat adipocyte), If the 
i~ for activation of skeletal muscle AMPK by ZMP is com- 
parable with rat adipocyte or liver enzymes then we believe 
enough AICAR was metabolised to ZMP (estimated to be 460 
pM) to cause activation of AMPK in the isolated soleus mus- 
cle preparations. Clearly, future studies should establish the 
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magnitude and degree of allosteric activation of skeletal mus- 
cle AMPK by ZMP. The lack of studies on measurement of 
AMPK activity in skeletal muscle cells suggests there are pro- 
blems with the assay of this enzyme in this tissue. Neverthe- 
less, future studies will be needed to determine the effect of 
AICAR on AMPK activity and the phosphorylation status 
and activity of phosphorylase kinase in skeletal muscle. 
Finally, the present study has shown that the AICAR-stim- 
ulated increase in phosphorylase activity or net lactate release 
is potently inhibited by insulin (Fig. 5). The concentration of
insulin required for half-maximal ctivation of processes like 
glucose transport, glycogen synthesis or glucose oxidation in 
skeletal muscle is about 100 ttUnits/ml [15,17]. The AICAR- 
stimulated rate of net lactate release and phosphorylase activ- 
ity is inhibited by almost 90°/'0 at 100 ttUnits of insulin/ml 
(Fig. 5). This finding agrees with results from an in vivo rat 
study that shows that glycogenolysis inskeletal muscle is more 
sensitive to insulin than is glucose transport and phosphoryla- 
tion [1]. Interestingly, if AICAR does activate phosphorylase 
kinase our results uggests that phosphorylase kinase does not 
phosphorylate o inactivate glycogen synthase (Fig, 1), as has 
been previously suggested [27]. 
In conclusion we have shown that AICAR activates glyco- 
genolysis and stimulated glycogen phosphorylase activity in 
skeletal muscle by ZMP. These effects are possibly caused 
by a mechanism involving activation of AIV;,'K, rather than 
direct allosteric activation of phosphorylase by ZMP. During 
contraction or electrical stimulation or anoxia in skeletal mus- 
cle there is a significant increase in the concentration of free 
AMP [28]. We speculate that a rise in AMP during contrac- 
tion is a novel mechanism to activate glycogenolysis via acti- 
vation of AMPK. 
Acknowledgements: This work was funded in part by Zeneca Pharma- 
ceuticals, the M.R.C. and the British Heart Foundation. 
References 
[!] Rosetti, L. and Hu, M. (1993) J. Clin. Invest. 92, 2963-2974. 
[2] Schulman, R.G. (1988) TIBS 13, 37-39. 
[3] Carling D, and Hardie, D,G. (1989) Biochim. Biophys. Acta 
1012, 81-86. 
[4] Carling, D,, Zammit, V.A. and Hardie, D.G. (1987) FEBS Lett. 
223, 217-222. 
[5] Hardie, G.D., Carling, D. and Sim, T.R. (1989) TIBS 14, 20-23. 
[6] Sullivan, J.E., Brocklehurst, KJ., Marley, A.E., Carey, F., 
Carling, D. and Beri, R.K. (1994) FEBS Lett. 353, 33-36. 
[7] Gillespie, J.G. and Hardie, G.D. (1992) FEBS Lett. 306, 59-62. 
[8] Sullivan, J.E., Carey, F. and Beri, R.K. (1994) Biochem. Biophys. 
Res. Commun. 200, 1551-1556. 
[9] Sire, A.T.R. and Hardie, D.G. (1988) FEBS Lett. 233, 294-298. 
[10] Bontemps, F., Vanden Berghe, G. and Hers, H.G. (1986) J. Clin. 
Invest. 77, 824--830. 
[I !] Javaux, F., Vincent, M.F., Wagner, D.R. and Van De Berghe, G. 
(1995) Biochem. J 305, 913-919. 
[12] Corton, J.M., Gillespie, J.G., Hawley, S.A. and Hardie, D.G. 
(1995) Eur. J. Biochem. 229, 558-565. 
[13] Carling, D., Clarke, P.R., Zammit, V.A. and Hardie, D.G. (1989) 
Eur. J. Biochem. 186, 129-136. 
[14] Weekes, J., Ball, K.L., Caudwell, F.B. and Hardie, D.G. (1993) 
FEBS Lett. 334, 335-339. 
[15] Vincent, M.F., Maragangos, P.J., Gruber, H.E. and Van Den 
Berghe, G. (1991) Diabetes 40, 1259-1266. 
[16] Vincent F., Bontemps, F. and Van Den Berghe, G. (1992) Bio- 
chem. J. 281,267-272. 
[17] Challiss, R.AJ., Espinai, J. and Newsholme, E.A. (1983) Biosci. 
Rep. 3, 675-679. 
M.E. Young et ai.IFEBS Letters 382 (1996) 43--47 47 
[18] Leighton, B., Budohoski, L., Lozeman, F.J., Challiss, R.A.J. and 
Newsholme, E.A. (1985) Biochem. J. 227, 337-344. 
[19] Dimitriadis, G., Parry-Billings, M., Leighton, B., Piva, T., Dun- 
ger, D., Calder, P., Bond, J. and Newsholme, E.A. (1994) Eur. J. 
Clin. Invest. 24, 161-165. 
[20] Stalmans, W. and Hers, H.G. (1975) Eur. J. Biochem. 54, 341- 
350. 
[21] Newsholme, E.A. and Leech, A.R. (1990) John Wiley and Sons, 
Chicester, UK, pp. 323-328. 
[22] Swain, J.L., Hines, J.J., Sabina, R.L., Harbury, O.L. and 
Holmes, E.W. (1984) J. Clin. Invest. 74, 1422-1427. 
[23] Sabina, R.L., Kernstine, K.H., Boyd, R.L., Holmes, E.W. and 
Swain, J.L. 0982) J. Biol. Chem. 257, 10178-I0183. 
[24] Bevan, S. 0992) D.Phil thesis, Oxford. 
[25] Arch, J.R.S. and Newsholme, E.A. (1978) Bicochem. J. 174, 965- 
977. 
[26] Davies, S.P., Calling, D. and Hardie, D.G. (1989) Eur. J. Bio- 
chem. 186, 123-128. 
[27] Cohen, P. (1987) Bioessays 2, 63-68. 
[28] Dudley, A. and Terjung, R.L. (1985) Am. J. Physiol. 248, C43- 
C50. 
